Additional phase 2 trials using nilotinib in KIT-mutant melanoma patients (including MM) exhibited similar responses as seen with imatinib, demonstrating a clinical effect in patients with disease progression imatinib [90,91,92,93,94]. The gene discussed is KIT; the disease is Miyoshi myopathy.